Skip to content
Review Open access

Research progress and challenges of stem cell therapy for Parkinson's disease

Sep 2026 · Journal of Clinical Technology and Theory · 0 citations

TL;DR

Stem cell therapy, leveraging self-renewal, multi-directional differentiation and paracrine regulation, has become a research hotspot in the field of PD treatment, bringing new hope for the radical cure of PD.

Abstract

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, leading to striatal dopamine depletion and resulting motor (e.g., tremor, bradykinesia) and non-motor symptoms (e.g., cognitive decline and sleep abnormalities). Current treatment strategies mainly focus on dopamine replacement therapy and deep brain stimulation. Although these methods can temporarily relieve symptoms, they cannot reverse nerve damage, and long-term use is associated with obvious side effects and potential risks. There is thus an urgent clinical need for new radical treatment methods. Stem cell therapy, leveraging self-renewal, multi-directional differentiation and paracrine regulation, has become a research hotspot in the field of PD treatment, bringing new hope for the radical cure of PD. This review synthesizes the research status and core issues of stem cell therapy for PD, offering practical insights for future research and clinical trials, and promoting the standardization and interdisciplinary development of regenerative neuroscience.

Read PDF

Similar papers

Review Aug 2026

Regenerative medicine for neurodegenerative diseases:History, Strategies, and Clinical Advances.

This review traces the historical evolution of regenerative therapies for NDDs - from early exploratory cell transplantation to modern approaches involving pluripotent stem cells (PSCs) and in vivo direct reprogramming and elucidate the core strategies of regenerative medicine within an integrated framework encompassin...

Jia Li, Hongmei Duan, Peng Hao et al. · 0 citations
Review

Advances in Modern Biomedicine

The urgent need for reliable biomarkers, early diagnosis, and multidisciplinary disease-modifying strategies for future therapeutic interventions is highlighted, with particular emphasis on challenges associated with bench-to-bedside translation.

Jeewanjot Singh, Subhi Sharma, Prabhjot Singh et al. · 0 citations
Review Aug 2026

Nanotechnology-enabled delivery of bioactive compounds for neuroprotection in Parkinson's disease: mechanisms and future directions.

This approach aims not only to control symptoms but also to potentially control neurodegeneration in PD, and the major challenges include large-scale production, long-term safety assessment, regulatory challenges, and site-specific delivery.

P. Gaur, Prachee Raje Bisht, Sonia Lal Gupta · 0 citations
Review Open access Sep 2026

Dopamine-replacing gene therapy for Parkinson's disease: biochemical background and current clinical experience.

This review summarizes the metabolism, physiological functions, and pathophysiology of dopamine in the striatum and discusses clinical studies investigating gene transfer of dopamine-synthesizing enzymes into the striatum.

H. Ichinose, Yo Sato, Shin-ichi Muramatsu · 0 citations
Review Open access Sep 2026

Research Progress on the Pathogenesis of Parkinson's Disease and the Neuroregulatory Mechanism of Deep Brain Stimulation Based on Animal Models

This paper systematically reviews the experimental evidence supporting the regulatory role of deep brain stimulation at multiple levels, including the correction of abnormal neural discharges, the attenuation of pathological neural oscillations, the modulation of neurotransmitter transmission, the remodelling of synapt...

Yi-Ding Peng · 0 citations
Review Open access Aug 2026

A Narrative Review on the Role of Stem Cells in Neurodegenerative Disorders

This review critically discusses current developments, ongoing clinical trials, therapeutic mechanisms, and key challenges associated with stem cell-based interventions, and translational barriers that must be addressed for the successful clinical implementation of stem cell therapies in neurodegenerative diseases.

Sujatha Krishnamoorthy, Vibhusha Venkatesan, Urbi Roy · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.